Pfizer sees $10 bln-$15 bln in annual mRNA vaccine revenue by 2030
Dec 12 (Reuters) - U.S. drugmaker Pfizer Inc (PFE.N) said on Monday it expects $10 billion to $15 billion in annual global revenue by 2030 from its portfolio of mRNA vaccines, which includes its COVID-19 vaccine as well as shots for flu and shingles. Reporting by Bhanvi Satija in Bengaluru and…#newjersey #shinjiniganguli #bhanvisatija #mrna #pfizerinc #bengaluru #michaelerman
Source: Reuters: Health - Category: Consumer Health News Source Type: news
More News: Covid Vaccine | COVID-19 | Health | Pfizer | Shingles | Shingles (Herpes Zoster) Vaccine | Vaccines